Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia

Background. Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount o...

Full description

Bibliographic Details
Main Authors: Susi Susanah, Ponpon S. Idjradinata, Nur M. Sari, Lulu E. Rakhmilla, Yunia Sribudiani, Jessica O. Trisaputra, Octawyana Moestopo
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2020/8185016
id doaj-3530997fec1d46ceb90c84ceb8e32e03
record_format Article
spelling doaj-3530997fec1d46ceb90c84ceb8e32e032020-12-28T01:30:28ZengHindawi LimitedBioMed Research International2314-61412020-01-01202010.1155/2020/8185016Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-ThalassemiaSusi Susanah0Ponpon S. Idjradinata1Nur M. Sari2Lulu E. Rakhmilla3Yunia Sribudiani4Jessica O. Trisaputra5Octawyana Moestopo6Department of Child HealthDepartment of Child HealthDepartment of Child HealthDepartment of Public HealthDepartment of Biomedical SciencesFaculty of MedicineFaculty of MedicineBackground. Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount of transfusion regarding the time to start iron chelator, and serum hepcidin levels in newly diagnosed severe β-thalassemia. Methods. A prospective cohort study was performed at Hasan Sadikin General Hospital on newly diagnosed severe β-thalassemia patients. Subjects had not received any blood transfusion with normal liver function test, CRP, and IL-6 levels who consumed normal diet according to age. The SF and TS levels indicate iron status, while hepcidin level indicates iron regulator status. Main indicator to start iron chelation therapy when SF level ≥1.000 ng/mL, TS level ≥70%, or after receiving transfusion at least 10 times. Statistical analysis used Mann–Whitney and Spearman. Results. Forty-two newly severe β-thalassemia, 30 (71.4%), were diagnosed before 1 year old, mean 9.9±6.4 months, range 2–24 months. Range amount of transfusion until SF level reached ≥1,000 ng/mL were 4-12 times, mean 7±2 times. Mean SF and TS level at diagnosis were 365.6±194.9 ng/mL and 67.3±22.5%, while hepcidin level was normal, mean 242.6±58 ng/mL. 36/42 patients have reached SF >1000 ng/mL with amount of transfusion less than 10 times. There was no significant difference of SF, TS, and hepcidin levels when SF >1000 ng/mL in the group with amount of transfusion 7–12 and less than 7 (p=0.454, p=0.084, p=0.765), respectively. A significant positive correlation between SF and amount of transfusion was observed (p<0.001; r=0.781). Conclusion. Iron overload in severe β-thalassemia patients might occur earlier even before they received 10 times transfusion. Hepcidin serum level tends to increase when iron overload just started.http://dx.doi.org/10.1155/2020/8185016
collection DOAJ
language English
format Article
sources DOAJ
author Susi Susanah
Ponpon S. Idjradinata
Nur M. Sari
Lulu E. Rakhmilla
Yunia Sribudiani
Jessica O. Trisaputra
Octawyana Moestopo
spellingShingle Susi Susanah
Ponpon S. Idjradinata
Nur M. Sari
Lulu E. Rakhmilla
Yunia Sribudiani
Jessica O. Trisaputra
Octawyana Moestopo
Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
BioMed Research International
author_facet Susi Susanah
Ponpon S. Idjradinata
Nur M. Sari
Lulu E. Rakhmilla
Yunia Sribudiani
Jessica O. Trisaputra
Octawyana Moestopo
author_sort Susi Susanah
title Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_short Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_full Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_fullStr Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_full_unstemmed Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_sort time to start delivering iron chelation therapy in newly diagnosed severe β-thalassemia
publisher Hindawi Limited
series BioMed Research International
issn 2314-6141
publishDate 2020-01-01
description Background. Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount of transfusion regarding the time to start iron chelator, and serum hepcidin levels in newly diagnosed severe β-thalassemia. Methods. A prospective cohort study was performed at Hasan Sadikin General Hospital on newly diagnosed severe β-thalassemia patients. Subjects had not received any blood transfusion with normal liver function test, CRP, and IL-6 levels who consumed normal diet according to age. The SF and TS levels indicate iron status, while hepcidin level indicates iron regulator status. Main indicator to start iron chelation therapy when SF level ≥1.000 ng/mL, TS level ≥70%, or after receiving transfusion at least 10 times. Statistical analysis used Mann–Whitney and Spearman. Results. Forty-two newly severe β-thalassemia, 30 (71.4%), were diagnosed before 1 year old, mean 9.9±6.4 months, range 2–24 months. Range amount of transfusion until SF level reached ≥1,000 ng/mL were 4-12 times, mean 7±2 times. Mean SF and TS level at diagnosis were 365.6±194.9 ng/mL and 67.3±22.5%, while hepcidin level was normal, mean 242.6±58 ng/mL. 36/42 patients have reached SF >1000 ng/mL with amount of transfusion less than 10 times. There was no significant difference of SF, TS, and hepcidin levels when SF >1000 ng/mL in the group with amount of transfusion 7–12 and less than 7 (p=0.454, p=0.084, p=0.765), respectively. A significant positive correlation between SF and amount of transfusion was observed (p<0.001; r=0.781). Conclusion. Iron overload in severe β-thalassemia patients might occur earlier even before they received 10 times transfusion. Hepcidin serum level tends to increase when iron overload just started.
url http://dx.doi.org/10.1155/2020/8185016
work_keys_str_mv AT susisusanah timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT ponponsidjradinata timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT nurmsari timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT luluerakhmilla timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT yuniasribudiani timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT jessicaotrisaputra timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT octawyanamoestopo timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
_version_ 1714981096736686080